Intensity Therapeutics To Present Data For First Seven Participants In Group A In INVINCIBLE-4 Trial In ePoster By The Swiss Cancer Institute At ESMO 2026 Virtual Congress Platform
Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its
Intensity Therapeutics will show early patient results from their cancer medicine trial. When a company shares patient data, watch whether doctors think it is working.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.